GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder

Feb 21, 2025Endocrinology

GLP-1 Receptor Agonists as Potential Treatments for Alcohol Use Disorder

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

may decrease alcohol intake and reduce motivation to consume alcohol.

Preclinical studies indicate that GLP-1 receptor agonists can prevent relapse drinking.
Human studies confirm that GLP-1 receptor agonists reduce alcohol intake in patients with .
Genetic variations in the GLP-1 receptor are associated with alcohol use disorder and heavy drinking.
The mechanisms through which GLP-1 affects alcohol-related behaviors may involve reward-processing areas in the brain.

AI simplified

Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addiction. Specifically, preclinical studies demonstrated that GLP-1 receptor agonists decrease alcohol intake, reduce the motivation to consume alcohol, and prevent relapse drinking by potentially lowering alcohol-induced reward. These preclinical results have been confirmed and extended in human studies in which GLP-1 receptor agonists reduce alcohol intake in patients with (AUD) who have a regular weight or comorbidity of obesity or type 2 diabetes. On a similar note, genetic variations in genes encoding for the GLP-1 receptor are associated with AUD and heavy drinking. The central mechanisms by which GLP-1 regulates alcohol-related behaviors are not fully defined, but may involve areas central to reward as well as regions projecting to these reward areas, such as the nucleus tractus solitarius of the brainstem. Together, existing preclinical and clinical data suggest that GLP-1 is involved in the AUD process and implies its role as a tentative treatment for AUD.

Key numbers

12 weeks

Reduction in alcohol intake

Duration of dulaglutide treatment reducing alcohol intake in patients with .

2 separate population cohorts

Genetic association

Population cohorts showing SNP associations with diagnosis.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text ↗

GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief